New Drug in Primary Care 2017 Lesinurad (Zurampic)® Ironwood ...................................................................................... 3 Pharmacology ................................................................................................................3 Pharmacokinetics ..........................................................................................................3 Clinical Trials .................................................................................................................3 Adverse Effects..............................................................................................................4 Do sing ............................................................................................................................4 Cost ...............................................................................................................................4 Lifitegrast (Xiidra®) Shire ..................................................................................................... 4 Pharmacology ................................................................................................................4 Pharmacokinetics ..........................................................................................................4 Clinical Trials .................................................................................................................5 Adverse Effects..............................................................................................................5 Do sing ............................................................................................................................5 Cost ...............................................................................................................................5 Insulin glargine injection (Basaglar®) Boehringer Ingelheim/Lilly ........................... 5 Pharmacology ................................................................................................................5 Pharmacokinetics ..........................................................................................................6 Clinical Trials .................................................................................................................6 Adverse Effects..............................................................................................................6 Do sing ............................................................................................................................6 Cost ...............................................................................................................................6 Lixisenatide (Adlyxin®) Sanofi............................................................................................ 7 Pharmacology ................................................................................................................7 Pharmacokinetics ..........................................................................................................7 Clinical Trials .................................................................................................................7 Adverse Effects..............................................................................................................8 Do sing ............................................................................................................................8 Cost ...............................................................................................................................8 Insulin glargine and lixisenatide (Soliqua 100/33®) Sanofi ......................................... 8 Pharmacology ................................................................................................................8 Pharmacokinetics ..........................................................................................................8 Clinical Trials .................................................................................................................9 Adverse Effects..............................................................................................................9 Do sing ............................................................................................................................9 Cost ...............................................................................................................................9 Bezlotoxumab (Zinplava®) Merck .................................................................................... 10 Pharmacology .............................................................................................................. 10 Pharmacokinetics ........................................................................................................ 10 Clinical Trials ............................................................................................................... 10 Adverse Effects............................................................................................................ 10 Do sing .......................................................................................................................... 11 Cost ............................................................................................................................. 11 Crisaborole (Eucrisa®) Anacor ......................................................................................... 11 Pharmacology .............................................................................................................. 11 Pharmacokinetics ........................................................................................................ 11 Clinical Trials ............................................................................................................... 11 Adverse Effects............................................................................................................ 11 Do sing .......................................................................................................................... 12 Cost ............................................................................................................................. 12 Elbasvir and Grazoprevir (Zepatier®) Merck ................................................................. 12 Pharmacology .............................................................................................................. 12 Pharmacokinetics ........................................................................................................ 12 Clinical Trials ............................................................................................................... 12 Adverse Effects............................................................................................................ 13 Do sing .......................................................................................................................... 13 Cost ............................................................................................................................. 13 Sofosbuvir/velpatasvir (Epclusa®) Gilead ..................................................................... 14 Pharmacology .............................................................................................................. 14 Pharmacokinetics ........................................................................................................ 14 Clinical Trials ............................................................................................................... 14 Adverse Effects............................................................................................................ 15 Do sing .......................................................................................................................... 15 Cost ............................................................................................................................. 15 Patiromer (Veltassa®) Relypsa ......................................................................................... 15 Pharmacology .............................................................................................................. 15 Pharmacokinetics ........................................................................................................ 15 Clinical Trials ............................................................................................................... 16 Adverse Effects............................................................................................................ 16 Do sing .......................................................................................................................... 16 Cost ............................................................................................................................. 16 Mepolizumab (Nucala®) Glaxo .......................................................................................... 16 Pharmacology .............................................................................................................. 17 Pharmacokinetics ........................................................................................................ 17 Clinical Trials ............................................................................................................... 17 Adverse Effects...........................................................................................................